ClinicalTrials.gg
CompletedNCT00406211Updated Sep 15, 2016

Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine

A Phase 3 interventional study of MMRV and MMR (Priorix®) in Rubella, Varicella and Mumps, sponsored by GlaxoSmithKline. Completed at 41 sites in 2 countries. Open to participants aged 12 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Phase
Phase 3
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
12 Months to 18 Months
Sex
All
01

Study summary

Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' measles-mumps-rubella (MMR) vaccine (Priorix®) and varicella vaccine (Varilrix®) in Germany \& Austria. Blood samples were collected at three time points during the follow-up period (Year 1, 2 \& 3). No new subjects will be enrolled in these follow-up phases of the study.

02

Conditions studied

  • Rubella
  • Varicella
  • Mumps
  • Measles

Keywords

  • Rubella
  • Varicella
  • Measles
  • Mumps
  • Germany
  • Austria
03

In context

Rubella

85 studies on the registry are indexed under Rubella; 11 are open to participants now.

This study's enrollment of 398 is below the median of 801 across 71 interventional studies indexed under Rubella.

Browse Rubella studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 118 are open to participants now.

Of its 264 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 18 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from the parents/guardians of the child before participating in the long-term follow-up.
  • Subjects must have received their complete vaccination course according to the group allocation (i.e. subjects must have received either two doses of MMRV combined vaccine, or two doses of Priorix vaccine and one dose of Varilrix vaccine as separate injections in the primary vaccination study.
  • Subjects were aged between 12 to 18 months of age at the time of the first vaccination in the primary study.

Exclusion criteria

Exclusion Criteria:

  • Subjects must not have received an additional dose of measles, mumps, rubella or varicella containing vaccines.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
398 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Seropositivity rate & antibody titers for MMRV at 1, 2 & 3 year

  2. Occurrence of breakthrough cases & contacts with MMRV disease(s) for 3 years after vaccination

07

Study locations

41 sites
  • GSK Investigational Site
    Klagenfurt, A-9020, Austria
  • GSK Investigational Site
    Neufeld/Leitha, A 2491, Austria
  • GSK Investigational Site
    Salzburg, A-5020, Austria
  • GSK Investigational Site
    Villach, A-9500, Austria
  • GSK Investigational Site
    Bindlach, Bayern 95463, Germany
  • GSK Investigational Site
    Marktredwitz, Bayern 95615, Germany
  • GSK Investigational Site
    Olching, Bayern 82140, Germany
  • GSK Investigational Site
    Tegernsee, Bayern 83684, Germany
  • GSK Investigational Site
    Tutzing, Bayern 82327, Germany
  • GSK Investigational Site
    Bad Camberg, Hessen 65520, Germany
  • GSK Investigational Site
    Fulda, Hessen 36037, Germany
  • GSK Investigational Site
    Hochheim, Hessen 65239, Germany
  • GSK Investigational Site
    Marburg/Lahn, Hessen 35039, Germany
  • GSK Investigational Site
    Nidderau, Hessen 61130, Germany
  • GSK Investigational Site
    Ruesselsheim, Hessen 65428, Germany
  • GSK Investigational Site
    Wiesbaden, Hessen 65205, Germany
  • GSK Investigational Site
    Salzgitter, Niedersachsen 38226, Germany
  • GSK Investigational Site
    Wolfenbuettel, Niedersachsen 38302, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • GSK Investigational Site
    Detmold, Nordrhein-Westfalen 32756, Germany
  • GSK Investigational Site
    Guetersloh, Nordrhein-Westfalen 33332, Germany
  • GSK Investigational Site
    Kirchlengern, Nordrhein-Westfalen 32278, Germany
  • GSK Investigational Site
    Loehne, Nordrhein-Westfalen 32584, Germany
  • GSK Investigational Site
    Muenster, Nordrhein-Westfalen 48159, Germany
  • GSK Investigational Site
    Bad Kreuznach, Rheinland-Pfalz 55543, Germany
  • GSK Investigational Site
    Bad Sobernheim, Rheinland-Pfalz 55566, Germany
  • GSK Investigational Site
    Frankenthal, Rheinland-Pfalz 67227, Germany
  • GSK Investigational Site
    Gau-Algesheim, Rheinland-Pfalz 55435, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55116, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Schoeneberg - Kuebelberg, Rheinland-Pfalz 66901, Germany
  • GSK Investigational Site
    Trier, Rheinland-Pfalz 54290, Germany
  • GSK Investigational Site
    Worms, Rheinland-Pfalz 67547, Germany
  • GSK Investigational Site
    Altenholz, Schleswig-Holstein 24161, Germany
  • GSK Investigational Site
    Bredstedt, Schleswig-Holstein 25821, Germany
  • GSK Investigational Site
    Brunsbuettel, Schleswig-Holstein 25541, Germany
  • GSK Investigational Site
    Flensburg, Schleswig-Holstein 24937, Germany
  • GSK Investigational Site
    Flensburg, Schleswig-Holstein 24943, Germany
  • GSK Investigational Site
    Husum, Schleswig-Holstein 25813, Germany
  • GSK Investigational Site
    Neumuenster, Schleswig-Holstein 24534, Germany
  • GSK Investigational Site
    Hamburg, 22089, Germany
08

References and documents

Publications

  • Habermehl P, Zepp F, Sänger R, Otto W, Helm K, Meister N, Knuf M, Kindler K, Willems P. Assessment of Varicella Breakthrough Cases One Year after Administration of Two Doses of a Measles, Mumps, Rubella, Varicella Vaccine in the Second Year of Life. Abstract presented at the 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Basel, Switzerland, 03-05 May 2006.
  • Knuf M, Faber J, Barth I, Habermehl P. A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc). 2008 Apr;44(4):279-92. doi: 10.1358/dot.2008.44.4.1210755. PubMed 18536786 ↗
  • Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Eur J Pediatr. 2012 Mar;171(3):463-70. doi: 10.1007/s00431-011-1569-4. Epub 2011 Sep 21. PubMed 21935584 ↗
  • Zepp F et al. Persistence of Functional Antibodies against Mumps Remains High One Year after Administration of Two Doses of a Measles, Mumps, Rubella, Varicella (MMRV) Vaccine in the Second Year of Life. Presented at 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Basel, Switzerland, 03-05 May 2006.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2006
First posted
Dec 4, 2006
Start
Jul 2004
Primary completionActual
Dec 2004
CompletionActual
Dec 2004
Last update
Sep 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00406211
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 4, 2006
Start date
Jul 2004
Primary completion
Dec 2004
Completion
Dec 2004
Last update
Sep 15, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Measles-Mumps-Rubella Vaccine

Start the discussion